Ronna Sue Cohen buys $3,747,669 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Ronna Sue Cohen scooped up 3,681 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 13, 2016. The investment management firm now holds a total of 89,294 shares of Abbott Laboratories which is valued at $3,747,669.Abbott Laboratories makes up approximately 2.73% of Ronna Sue Cohen’s portfolio.

Other Hedge Funds, Including , Culbertson A N Co Inc boosted its stake in ABT in the latest quarter, The investment management firm added 4,145 additional shares and now holds a total of 99,879 shares of Abbott Laboratories which is valued at $4,191,922. Abbott Laboratories makes up approx 1.51% of Culbertson A N Co Inc’s portfolio.Benin Management Corp boosted its stake in ABT in the latest quarter, The investment management firm added 52,460 additional shares and now holds a total of 78,728 shares of Abbott Laboratories which is valued at $3,304,214. Abbott Laboratories makes up approx 1.67% of Benin Management Corp’s portfolio.Benjamin F. Edwards Company boosted its stake in ABT in the latest quarter, The investment management firm added 553 additional shares and now holds a total of 11,549 shares of Abbott Laboratories which is valued at $484,712. Abbott Laboratories makes up approx 0.09% of Benjamin F. Edwards Company’s portfolio.Cohen Lawrence B boosted its stake in ABT in the latest quarter, The investment management firm added 6,775 additional shares and now holds a total of 98,484 shares of Abbott Laboratories which is valued at $4,125,495. Abbott Laboratories makes up approx 2.42% of Cohen Lawrence B’s portfolio.Cullinan Associates Inc reduced its stake in ABT by selling 12,200 shares or 3.96% in the most recent quarter. The Hedge Fund company now holds 295,750 shares of ABT which is valued at $11,693,955. Abbott Laboratories makes up approx 0.95% of Cullinan Associates Inc’s portfolio.

Abbott Laboratories closed down -0.01 points or -0.02% at $42.09 with 75,24,201 shares getting traded on Monday. Post opening the session at $42.05, the shares hit an intraday low of $41.81 and an intraday high of $42.229 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.39. The company had revenue of $4885.00 million for the quarter, compared to analysts expectations of $4777.68 million. The company’s revenue was down -.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.47 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.